New medication approved for drug-resistant HIV - WVVA TV Bluefield Beckley WV News, Weather and Sports

New medication approved for drug-resistant HIV

Updated:
  • Featured Health SponsorsFeatured Health SponsorsMore>>

  • Four Seasons Pharmacy Princeton, WV

    Four Seasons Pharmacy Princeton, WV


    Since opening in October 1998, Four Seasons Pharmacy has provided Southern West Virginia and Southwest Virginia a unique shopping experience. Now with the Shoppes at Willow Crossing, we offer a complete shopping area.
    More >>

    Since opening in October 1998, Four Seasons Pharmacy has provided Southern West Virginia and Southwest Virginia a unique shopping experience. Now with the Shoppes at Willow Crossing, we offer a complete shopping area.
    More >>
  • Princeton Health Care Center – Long Term Care

    Princeton Health Care Center – Long Term Care


    PHCC is a modern 120-bed nursing center offering the highest quality care available, with an emphasis toward the physical, social and emotional rehabilitation of our residents.
    More >>

    PHCC is a modern 120-bed nursing center offering the highest quality care available, with an emphasis toward the physical, social and emotional rehabilitation of our residents.
    More >>

(HealthDay News) -- Trogarzo (ibalizumab-uiyk) has been approved by the U.S. Food and Drug Administration to treat AIDS-causing HIV that has not responded to other antiretroviral medications.

Trogarzo is given intravenously once every 14 days in combination with other antiretroviral drugs, the FDA said Tuesday in a news release.

"While most patients living with HIV can be successfully treated using a combination of two or more antiretroviral drugs, a small percentage of patients who have taken many HIV drugs in the past have multidrug resistant HIV, limiting their treatment options," said Dr. Jeff Murray, deputy director of the agency's Division of Antiviral Products.

"Trogarzo is the first drug in a new class of antiretroviral medications that can provide significant benefit to patients who have run out of HIV treatment options," Murray added.

Trogarzo was evaluated in clinical studies involving 40 people who continued to have high blood levels of HIV, despite use of antiretroviral drugs. After 24 weeks of Trogarzo and other drugs, 43 percent of trial participants achieved HIV suppression, the FDA said.

The most common adverse reactions to Trogarzo were diarrhea, dizziness, nausea and rash. More severe side effects included immune system abnormalities.

Trogarzo is produced by TaiMed Biologics, based in Taiwan.

More information

Visit the FDA to learn more about Trogarzo.

Copyright © 2018 HealthDay. All rights reserved.

*DISCLAIMER*: The information contained in or provided through this site section is intended for general consumer understanding and education only and is not intended to be and is not a substitute for professional advice. Use of this site section and any information contained on or provided through this site section is at your own risk and any information contained on or provided through this site section is provided on an "as is" basis without any representations or warranties.
Powered by Frankly